Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?

類似資料

• Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives
  著者:: Rhee, Chin Kook, 等
  出版事項: (2019)
• Long-acting muscarinic antagonists vs. long-acting β (2) agonists in COPD exacerbations: a systematic review and meta-analysis
  著者:: Maia, Israel Silva, 等
  出版事項: (2017)
• A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD
  著者:: Sion, Katya Y. J., 等
  出版事項: (2017)
• Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
  著者:: Yamada, Hideyasu, 等
  出版事項: (2018)
• Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate
  著者:: Mahler, Donald A., 等
  出版事項: (2019)